Tesamorelin 10mg

Tesamorelin 10mg

$142.00

Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) designed to stimulate the pituitary gland to produce and release natural growth hormone. FDA-approved for the treatment of HIV-associated lipodystrophy, Tesamorelin effectively reduces excess abdominal fat in HIV-infected patients. Beyond its approved use, it has shown potential in improving body composition, addressing metabolic issues, and offering therapeutic benefits for conditions like non-alcoholic fatty liver disease (NAFLD) in HIV patients, making it a promising option for broader metabolic health applications.

Categories: ,

Description

Referenced Citations

  1. BMI Doctors. (2024). Tesamorelin Unveiled: Its Impact in Medical Science. [Online].
    Available: https://bmidoctors.com/tesamorelin-unveiled-its-impact-in-medical-science/
  2. LiverTox: Clinical and Research Information on Drug-Induced Liver Injury. (2018). Tesamorelin. [Online].
    Available: https://www.ncbi.nlm.nih.gov/books/NBK548730/
  3. Stanley, T.L., et al. (2014). Effect of Tesamorelin on Visceral Fat and Liver Fat in HIV-Infected Patients With Abdominal Fat Accumulation: A Randomized Clinical Trial. JAMA, 312(4), 380-389. [Online].
    Available: https://jamanetwork.com/journals/jama/fullarticle/1889139
  4. MedlinePlus. (2016). Tesamorelin Injection. [Online].
    Available: https://medlineplus.gov/druginfo/meds/a611035.html
  5. Falutz, J., et al. (2007). Metabolic Effects of a Growth Hormone–Releasing Factor in Patients with HIV. New England Journal of Medicine, 357(23), 2359-2370. [Online].
    Available: https://www.nejm.org/doi/full/10.1056/NEJMoa072375
  6. LIVV Natural. (2024). Tesamorelin and Gender in Hormone Therapies. [Online].
    Available: https://livvnatural.com/tesamorelin-and-the-gender-debate-should-hormone-therapies-be-gender-specific/
  7. Falutz, J., et al. (2010). Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. Journal of Clinical Endocrinology & Metabolism, 95(9), 4291-4304. [Online].
    Available: https://pubmed.ncbi.nlm.nih.gov/20554713/
  8. Stanley, T.L., et al. (2019). Effects of Tesamorelin on Non-alcoholic Fatty Liver Disease in HIV: A Randomised, Double-Blind, Multicentre Trial. The Lancet HIV. 6(12), e821-e830. [Online]. .
    Available: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6981288/

Related products